Cargando…

Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management

Despite the remarkable advances in the diagnosis and treatment of breast cancer patients, the presence or development of metastasis remains an incurable condition. Bone is one of the most frequent sites of distant dissemination and negatively impacts on patient’s survival and overall frailty. The in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Venetis, Konstantinos, Piciotti, Roberto, Sajjadi, Elham, Invernizzi, Marco, Morganti, Stefania, Criscitiello, Carmen, Fusco, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229615/ https://www.ncbi.nlm.nih.gov/pubmed/34199522 http://dx.doi.org/10.3390/cells10061377

Ejemplares similares

Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization
por: Sajjadi, Elham, et al.
Publicado: (2021)

Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials
por: de Sire, Alessandro, et al.
Publicado: (2022)

Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
por: Ivanova, Mariia, et al.
Publicado: (2023)

Impact of Rehabilitation on Breast Cancer Related Fatigue: A Pilot Study
por: Invernizzi, Marco, et al.
Publicado: (2020)

PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?
por: Fusco, Nicola, et al.
Publicado: (2020)

Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling
por: Sajjadi, Elham, et al.
Publicado: (2021)

Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients
por: Venetis, Konstantinos, et al.
Publicado: (2021)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Improving HER2 testing reproducibility in HER2-low breast cancer
por: Sajjadi, Elham, et al.
Publicado: (2022)

Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers
por: Venetis, Konstantinos, et al.
Publicado: (2020)

Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor—Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study
por: de Sire, Alessandro, et al.
Publicado: (2021)

Malignancies in Patients with Celiac Disease: Diagnostic Challenges and Molecular Advances
por: Ivanova, Mariia, et al.
Publicado: (2023)

Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema
por: Invernizzi, Marco, et al.
Publicado: (2020)

Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?
por: Sajjadi, Elham, et al.
Publicado: (2020)

Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods
por: Porta, Francesca Maria, et al.
Publicado: (2023)

Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test
por: Sajjadi, Elham, et al.
Publicado: (2023)

The molecular landscape of breast mucoepidermoid carcinoma
por: Venetis, Konstantinos, et al.
Publicado: (2023)

Editorial: Diagnosis and Treatment of Breast Cancer in 2022: The Rise of Novel Molecular Biomarkers
por: Fusco, Nicola, et al.
Publicado: (2023)

Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study
por: Blundo, Concetta, et al.
Publicado: (2021)

Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls
por: Morganti, Stefania, et al.
Publicado: (2022)

How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches
por: Ghidini, Michele, et al.
Publicado: (2021)

PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer
por: Lopez, Gianluca, et al.
Publicado: (2020)

Antibody–drug conjugates in solid tumors: a look into novel targets
por: Criscitiello, Carmen, et al.
Publicado: (2021)

Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis
por: Sajjadi, Elham, et al.
Publicado: (2023)

Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles
por: Sajjadi, Elham, et al.
Publicado: (2022)

Osteoclast-like stromal giant cells in breast cancer likely belong to the spectrum of immunosuppressive tumor-associated macrophages
por: Sajjadi, Elham, et al.
Publicado: (2022)

Editorial: Quality of Life in Breast Cancer Patients and Survivors
por: Invernizzi, Marco, et al.
Publicado: (2020)

Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation
por: Antonarelli, Gabriele, et al.
Publicado: (2023)

Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Impact of Physical Rehabilitation on Bone Biomarkers in Non-Metastatic Breast Cancer Women: A Systematic Review and Meta-Analysis
por: de Sire, Alessandro, et al.
Publicado: (2023)

Integrating molecular biomarkers in breast cancer rehabilitation. What is the current evidence? A systematic review of randomized controlled trials
por: Invernizzi, Marco, et al.
Publicado: (2022)

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
por: Fusco, Nicola, et al.
Publicado: (2021)

An Insight into Molecular Targets of Breast Cancer Brain Metastasis
por: Kaleem, Mohammed, et al.
Publicado: (2022)

Breast Cancer Genetics: Diagnostics and Treatment
por: Criscitiello, Carmen, et al.
Publicado: (2022)

How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?
por: Morganti, S., et al.
Publicado: (2022)

Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection
por: Criscitiello, Carmen, et al.
Publicado: (2010)

Microarrays bring new insights into understanding of breast cancer metastasis to bone
por: Welch, Danny R
Publicado: (2004)

Organotropism: new insights into molecular mechanisms of breast cancer metastasis
por: Chen, Wenjing, et al.
Publicado: (2018)

Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
por: Giugliano, Federica, et al.
Publicado: (2023)

Molecular Regulation of Bone Marrow Metastasis in Prostate and Breast Cancer
por: Rahim, Fakher, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_flsj1q24ng1179t0097snehq48